Ensure the security of your HCL environment by applying the Zero Trust princi...
Latest update USA Regulations By P.Trisler Qserve Group (Qserve Conference 2013)
1. The regulatory road to market
US FDA Regulations - Overview & Update
Qserve Conference 18-19 November 2013
Purmerend – Greater Amsterdam
Page 1 | 2011 |Copyright Qserve Group B.V.
2. Topics
•
Overview of FDA, Medical Device Classification System & Regulatory Processes
•
New Processes Impacting Many Programs
•
Refuse to Accept (RTA)
Electronic Copy (eCopy)
Changes related to Submissions
De Novo Application
•
Pre-De Novo Submission (PDS)
Pre-Submission (Pre-Sub)
Miscellaneous
Unique Device Identification (ID)
International Symbols
Medical Device Single Audit Program Pilot (MDSAP)
Page 2 | 2013 |Copyright Qserve Group B.V.
3. Topics
Additional New FDA Guidances – Clinical
•
Design Considerations for Pivotal Clinical Investigations for Medical Devices
-Guidance for Industry, Clinical Investigators, IRBs & FDA Staff (Nov, 2013)
•
Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical
Studies, Including Certain First in Human Studies (Oct 2013)
•
Oversight of Clinical Investigations – a Risk-Based Approach to Monitoring (Aug 2013)
•
(Draft) FDA Decisions for IDE Investigations (June 2013)
•
Financial Disclosure by Clinical Investigators (Feb 2013)
Page 3 | 2013 |Copyright Qserve Group B.V.
4. Overview FDA ….some facts…
Headed by a Commissioner (Margaret Hamburg, MD) appointed by US President
Headquartered in Washington, D.C – CDRH, CDER, CBER, CVM, etc
21 District Offices around the U.S.
Regulates > $1 trillion of products
Has regulatory authority over >65,000 establishments (not including entities under
BIMO – labs & clinical research sites)
Employs > 9,000 staff
Page 4 | 2013 |Copyright Qserve Group B.V.
5. US President
Health & Human Services
Food and Drug Administration
CDRH
ODE
CDER
CBER
ORA
OC
Div of BIMO
Page 5 | 2013 |Copyright Qserve Group B.V.
6. Overview – FDA’s Authority & Governance
US Congress: Federal Food, Drug & Cosmetic Act (1938), as amended…
The ‘device law’ (1976) -- Medical Device Amendments
Several amendments passed since that time
US Federal Agencies/FDA: Regulations
FDA Centers/Offices: Guidances/Guidelines/Points to Consider
Page 6 | 2013 |Copyright Qserve Group B.V.
7. Overview – US Federal Regulations
Title 21
Code of Federal Regulations (CFR)
Parts 1 – 99
General – for enforcement
of the FD&C Act
Parts 800 – 1299
Medical Devices &
Radiological Health
Page 7 | 2013 |Copyright Qserve Group B.V.
8. Overview – Regulations (21 CFR…)
Part 3 – Combination Products
Part 803 – Medical Device Reporting
Part 11 – Electronic Records
Part 807 – Premarket Notification/510(k),
Part 50 – Subject Protections
Part 54 – Financial Disclosure
Part 56 – IRB
Part 801, 809 – Labeling
Establishment Registration & Listing
Part 812 – IDE
Part 814 – HDE, PMA
Part 820
- QSR (GMP)
Page 8 | 2013 |Copyright Qserve Group B.V.
11. Overview
•
Classified by perceived/known risk & regulated accordingly
General
Controls
Class I
✔
Class III
✔
Premarket
Approval
✔
Class II
Special
Controls
✔
✔
Page 11 | 2013 |Copyright Qserve Group B.V.
12. Overview – General Controls
1.
Establishment Registration with FDA
2.
Medical Device Listing with FDA
3.
Manufacture devices according to QSR/GMP in 21 CFR Part 820.
4.
Label devices in accordance with labeling regulations in 21 CFR Part
801 or 809.
5.
Submit a Premarket Notification [510(k)] before marketing a device.
Page 12 | 2013 |Copyright Qserve Group B.V.
13. Overview – Special Controls
Examples
Special labeling requirements
Mandatory performance standards
Postmarket surveillance
Special Controls Guidance Document
Page 13 | 2013 |Copyright Qserve Group B.V.
14. Overview – Paths to the Market
Application
Type
Comments
Regulatory
Review
Product
Classes
510(k) =
Premarket
Notification
Substantially equivalent (“at least as safe &
effective as a legally marketed/predicate
device”)
90 days
Class II
generally
510(k)/de
novo Petition
Low to moderate risk; novel device. 510(k) must
conclude NSE bec no predicate device. Product
has to be shown to be safe & effective.
??
Class I/II
PMA =
Premarket
Approval
Reasonable assurance of safety & effectiveness
based on valid scientific evidence
180 days
Class III
HDE =
Humanitarian
Device
Exemption
For humanitarian use device (<4000 persons in
US/year). Evidence of safety and probable
benefit. Requires IRB approval for each use.
~75 HDEs approved by FDA
75 days
Class III
Page 14 | 2013 |Copyright Qserve Group B.V.
15. Overview – Device User Fees (2013-14)
Application Type
Standard
US $
*Small
Business
Premarket Approval Application
(PMA/PDP/BLA)
$258,520
$64,630
1st PMA from firm w/ sales/gross
receipts < $30 mil
n/a
$0
513(g) Classification Request
$3,490
$1,745
510(k) Premarket Notification
$5,170
$2,585
Annual Registration
$3,313
$3,313
*Small business = <$100M in gross receipts/
sales
Page 15 | 2013 |Copyright Qserve Group B.V.
16. New Processes
•
Refuse to Accept Policy for 510(k)s – RTA
•
31 Dec 2012
eCopy Program for Medical Device Submissions
10 Oct 2013
Page 16 | 2013 |Copyright Qserve Group B.V.
17. New – RTA
Key Points
Purpose: Administrative Review
To assure complete submissions - question of ‘completeness’ (administrative)
and not ‘quality of data’ (substantive).
FDA checklist
Provides specific information point-by-point of the elements/contents that are
considered ‘incomplete’.
15 calendar day post-submission review period
90-day substantive review clock starts on a determination of ‘completeness’.
Date will be the log-in date if no issues.
If there are issues & the RTA checklist is sent to applicant, the 90-day review
clock will not start until those have been resolved.
Page 17 | 2013 |Copyright Qserve Group B.V.
18. New – eCopy
•
(1)
Definition: Exact duplicate of paper copy, created and submitted on a CD, DVD or
flash drive. It is not a submission transmitted electronically.
•
Some exceptions regarding ‘exact duplicate’
Required for:
510(k)
PMA, traditional and modular
De Novo
PDP
IDE, with certain exceptions (compassionate use & emergency use)
Page 18 | 2013 |Copyright Qserve Group B.V.
19. New – eCopy
•
(2)
Requirements:
Technical standards for loading the file must be met (no exceptions) Particularly
important:
Naming convention (‘correct’ prefix: “001_”)
» Follow instructions closely with more than 1 volume
Files must be 50MB or smaller
Adobe Acrobat PDF Ver 11 or below
No embedded attachments
No security settings
Beware of special characters
Page 19 | 2013 |Copyright Qserve Group B.V.
20. New – eCopy
(3)
Consequences of incorrectly prepared eCopy:
Submission will not be accepted
and the date of receipt will not be the ‘log-in’ date.
However, FDA will hold the paper copy until a correctly-created
replacement eCopy has been received & loaded.
Page 20 | 2013 |Copyright Qserve Group B.V.
21. Submission Changes/Updates
•
De Novo Classification Process (Evaluation of Automatic Class III
Designation): Draft Guidance, 3 Oct 2011 (to replace a 1998 guidance)
•
Medical Devices: The Pre-Submission Program and Meetings with FDA
Staff: Draft Guidance 13 July 2012 (includes Pre-IDE Program)
Page 21 | 2013 |Copyright Qserve Group B.V.
22. Changes – De Novo Process
•
(1)
Authorization: 513(f)(2) of US Federal Food, Drug & Cosmetic Act (FD&C Act) –
passed in 1997, FDA Modernization Act (FDAMA)
•
Prior to 1997 all new devices, regardless of risk level, would have been
classified in Class III and require PMA.
•
•
De Novo = “Evaluation of Automatic Class III Designation”
Requirements for qualifying for de novo:
Low to moderate risk medical device
Novel (no predicate device/not previously classified)
NSE (not substantially equivalent) determination by FDA via 510(k), e.g ‘auto
classification into Class III’
File De Novo Petition
Page 22 | 2013 |Copyright Qserve Group B.V.
23. Changes – De Novo Process
•
(2)
Additional requirements to a successful petition
Risks & benefits need to be understood
‘Controls’ need to be possible to provide reasonable assurance of safety & effectiveness of the
device ‘type’
•
Those controls often include the conduct of clinical studies.
Good news if the new guidance is fully implemented: It provides for greater clarity &
transparency, in particular:
Pre de novo submission (PDS) >> 510(k)/De Novo Petition,
vs the ‘standard’:
510(k) >> De Novo Petition
90 de novo petitions granted to date.
Page 23 | 2013 |Copyright Qserve Group B.V.
24. Changes – Pre-Sub (Encompasses Pre-IDE)
•
Process that formalizes obtaining FDA’s pre-review for:
Non-clinical (laboratory & animal) protocol
Clinical protocol/design issues, prior to submitting an IDE
Pre-marketing submission interactions on a variety of topics (such as
uncertainty in method of presenting data, changes in device during IDE
study, discussion of problems encountered during conduct of clin study)
•
Specified format & content requirements
•
Timeline = 75-90 days
•
Feedback via teleconference, face-to-face meeting or written
(always receive written comments)
Page 24 | 2013 |Copyright Qserve Group B.V.
25. New – Unique Device Identifier (UDI) System
Implementation of US FD&C Act §519(f) (Sept, 2013).
Two key elements:
(1) Requires a UDI on devices & device packages (w/ some exceptions)
Must be marked on the device itself if the device is intended for use more than
once & intended for reprocessing before each use.
(2) Device labelers – info for each device labeled with UDI to FDA’s Global UDI
Database (GUDID).
Plain-text version & in a form that uses automatic ID & data capture tech.
All required device records must include the UDI.
7-year phase-in period (depending on risk level).
Page 25 | 2013 |Copyright Qserve Group B.V.
26. New – International Symbols
•
Currently – Medical Device Labeling (except for IVD) must accompany
international symbols with ‘words’.
•
Under consideration (proposed Rule) – Option on part of medical device
manufacturers to use standardized international symbols (recognized by FDA)
on labeling.
Page 26 | 2013 |Copyright Qserve Group B.V.
27. New – Medical Device Single Audit Program Pilot
•
Mission: Single audit program for medical device manufacturers
•
Sponsored by International Medical Device Regulators Forum (IMDRF)
•
January 2014 - FDA will begin participating in a MDSAP Pilot alongside other
international partner agencies:
•
•
•
Partners: Australia, Brazil, Canada
Observer: Japan
Pilot (Jan 2014 – Dec 2016) – auditing organizations: only those utilized by
Health Canada’s CMDCAS Program.
•
MDSAP for FDA:
•
routine inspections only
•
no ‘for cause’, no PMA (pre- or post-approval)
Page 27 | 2013 |Copyright Qserve Group B.V.
28. Thank you!
P a t s y Tr i s l e r
Qserve Group US Inc.
P a t s y. t r i s l e r @ q s e r v e g r o u p . c o m
www.qservegroup.com
Qserve Group B.V.
Asterweg 19 D12
1031 DL Amsterdam
The Netherlands
T +31 (0)20 78 82 630
E info@qservegroup.com
Page 28 | 2013 |Copyright Qserve Group B.V.